Statin Use in Advanced CKD Lowers Death Risk

Share this content:
Researchers report a significant 41% decreased mortality risk among patients with advanced CKD who used statins compared with those who did not.
Researchers report a significant 41% decreased mortality risk among patients with advanced CKD who used statins compared with those who did not.

Statin use is associated with a decreased risk of death among patients with advanced chronic kidney disease (CKD), according to researchers.

In a study of 10,204 patients with advanced CKD (all of whom had been prescribed erythropoiesis-stimulating agents for anemia), investigators found that statin users had a significant 41% reduction in death risk compared with a propensity score-matched group of non-users, Tao-Min Huang, MD, of National Taiwan University Hospital in Zhongzheng, Taipei, and colleagues reported in the Journal of Clinical Medicine. The reduction in death risk was due largely to a decrease in sepsis-related mortality. Statin use was associated with a significant 47% decreased risk of sepsis-related death.

Statins could help treat and prevent of sepsis by targeting a number of inflammatory and immune-modulating cascades involved in sepsis, the investigators explained.

“Our study supports the clinical benefit of statin therapy among advanced CKD patients in the reduction of all-cause mortality and especially sepsis-related mortality,” the authors wrote.

Statin use was not associated with development of new-onset diabetes mellitus (NODM) or decreased risk of new major adverse cardiovascular events (MACE).

The study compared 2551 new users of statins and a propensity score-matched group of 7653 who did not use statins. Statin users and non-users had a mean age of 59.4 and 59.7 years, respectively. Women made up approximately 64% of each group.

Reference

Huang TM, Wu VC, Lin YF, et al. Effects of statin use in advanced chronic kidney disease patients. J Clin Med. 2018;7(9).  pii: E285

You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup